Palvella Therapeutics (PVLA) EBIT Margin (2016 - 2024)
Historic EBIT Margin for Palvella Therapeutics (PVLA) over the last 11 years, with Q4 2024 value amounting to 2412.15%.
- Palvella Therapeutics' EBIT Margin rose 13816700.0% to 2412.15% in Q4 2024 from the same period last year, while for Dec 2024 it was 11011.72%, marking a year-over-year increase of 110393800.0%. This contributed to the annual value of 3277.91% for FY2024, which is 33056300.0% up from last year.
- Palvella Therapeutics' EBIT Margin amounted to 2412.15% in Q4 2024, which was up 13816700.0% from 3318.87% recorded in Q1 2024.
- In the past 5 years, Palvella Therapeutics' EBIT Margin ranged from a high of 2412.15% in Q4 2024 and a low of 3318.87% during Q1 2024
- For the 5-year period, Palvella Therapeutics' EBIT Margin averaged around 213.55%, with its median value being 163.66% (2021).
- Over the last 5 years, Palvella Therapeutics' EBIT Margin had its largest YoY gain of 13816700bps in 2024, and its largest YoY loss of -25471800bps in 2024.
- Quarter analysis of 5 years shows Palvella Therapeutics' EBIT Margin stood at 661.21% in 2020, then soared by 80bps to 130.27% in 2021, then plummeted by -51bps to 197.04% in 2022, then surged by 623bps to 1030.48% in 2023, then surged by 134bps to 2412.15% in 2024.
- Its EBIT Margin stands at 2412.15% for Q4 2024, versus 3318.87% for Q1 2024 and 1030.48% for Q4 2023.